VERZENIO (abemaciclib) tablets is used for the treatment of patients with metastatic breast cancer

VERZENIO™ is a kinase inhibitor indicated: • in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. • as monotherapy for the treatment of adult patients with HRpositive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

VERZENIO (abemaciclib) tablets suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of VERZENIO (abemaciclib) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Lynparza (olaparib) tablets cost price in India.

The order for VERZENIO (abemaciclib) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Abemaciclib (trade names Verzenio and Verzenios) is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. Abemaciclib is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

VERZENIO™ (abemaciclib) tablets, for oral use Initial U.S. Approval: 2017

Generic Name: abemaciclib

Tablets: 50 mg, 100 mg, 150 mg, and 200 mg

Verzenio (abemaciclib) tablets

Lynparza (olaparib) tablets, for oral use is available.

Get In Touch

Indian Pharma Network (IPN), Delhi. India

IPN, Delhi is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India. IPN, New Delhi helps patient, providing solutions on how to get access of anti cancer medicines which is not available in India.


Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

VERZENIO (abemaciclib) tablets suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand VERZENIO (abemaciclib) tablets on prescription and Import License in Patient's Name only.

For overseas patients, VERZENIO (abemaciclib) tablets can be made available in Send your enquiry to find VERZENIO (abemaciclib) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for VERZENIO (abemaciclib) tablets.

For VERZENIO (abemaciclib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

CDK4/6 Inhibitors for Breast Cancer: Who Does, Doesn't Benefit? For More Details

US FDA issues safety warning on three breast cancer drug